Ownership and insider activity for Corbus Pharmaceuticals Holdings, Inc. (CRBP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid typ...
Price
| Price | $7.26 |
| Market Cap | $135M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.0M | $62.5M | $41.7M | $31.7M | $85.4M | $25.0M | $17.0M | $13.7M | $17.2M | $28.5M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $72.6M | $42.2M | $7.2M | $131.9M | $134.8M |
| Receivables | $1.3M | 0 | 0 | $2.7M | $2.6M | 0 | 0 | 0 | 0 | $1.5M |
| Inventory | $0 | 0 | 0 | -$2.7M | $350000 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $17.4M | $65.5M | $44.2M | $38.2M | $92.1M | $100.2M | $60.2M | $23.5M | $153.0M | $167.0M |
| Property, Plant & Equipment | $435251 | $1.4M | $2.7M | $10.9M | $9.3M | $7.0M | $5.5M | $4.0M | $2.5M | $1.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $17.9M | $67.0M | $47.0M | $49.1M | $102.3M | $107.7M | $66.3M | $28.3M | $155.9M | $168.2M |
| Accounts Payable | $3.4M | $3.1M | $6.3M | $11.1M | $7.4M | $1.8M | $2.2M | $3.2M | $4.8M | $2.2M |
| Short-term Debt | $271757 | $332861 | $394305 | $752659 | $710158 | $3.9M | $3.1M | $16.2M | 0 | 0 |
| Total Current Liabilities | $8.9M | $8.2M | $18.1M | $34.9M | $31.9M | $17.0M | $12.6M | $31.9M | $11.8M | $20.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | $18.0M | $15.6M | $16.0M | 0 | 0 | 0 |
| Total Liabilities | $9.0M | $9.2M | $19.5M | $43.0M | $57.0M | $38.6M | $33.3M | $35.2M | $13.5M | $20.7M |
| Retained Earnings | -$33.3M | -$65.7M | -$121.4M | -$192.8M | -$304.1M | -$349.7M | -$392.1M | -$436.7M | -$476.9M | -$555.4M |
| Total Equity | $8.9M | $57.8M | $27.5M | $6.2M | $45.3M | $69.1M | $33.0M | -$6.9M | $142.4M | $147.5M |
| Total Debt | $276389 | $332861 | $394305 | $9.4M | $26.8M | $26.6M | $25.1M | $20.9M | $3.2M | $1.6M |
| Net Debt | -$14.7M | -$62.2M | -$41.4M | -$22.3M | -$58.6M | -$71.1M | -$34.1M | -$21000 | -$145.8M | -$162.3M |
| Working Capital | $8.5M | $57.3M | $26.2M | $3.3M | $60.2M | $83.2M | $47.5M | -$8.3M | $141.2M | $146.3M |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 5.71 |
Profitability
| Return on Equity | -87.05% |
| Return on Invested Capital | -100.35% |
| Return on Assets | -80.25% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALEC · APLT · CRDF · ELTX · FBRX · IPHA · MIST
Explore sector: Healthcare · Biotechnology
More sections of CRBP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks